HK1212336A1 - Azaquinazoline inhibitors of atypical protein kinase - Google Patents
Azaquinazoline inhibitors of atypical protein kinaseInfo
- Publication number
- HK1212336A1 HK1212336A1 HK16100191.9A HK16100191A HK1212336A1 HK 1212336 A1 HK1212336 A1 HK 1212336A1 HK 16100191 A HK16100191 A HK 16100191A HK 1212336 A1 HK1212336 A1 HK 1212336A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- azaquinazoline
- inhibitors
- protein kinase
- atypical protein
- atypical
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261707340P | 2012-09-28 | 2012-09-28 | |
US201361781364P | 2013-03-14 | 2013-03-14 | |
PCT/US2013/062085 WO2014052699A1 (en) | 2012-09-28 | 2013-09-27 | Azaquinazoline inhibitors of atypical protein kinase c |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1212336A1 true HK1212336A1 (en) | 2016-06-10 |
Family
ID=49326872
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15112771.3A HK1211928A1 (en) | 2012-09-28 | 2015-12-28 | Azaquinazoline inhibitors of atypical protein kinase |
HK16100191.9A HK1212336A1 (en) | 2012-09-28 | 2016-01-08 | Azaquinazoline inhibitors of atypical protein kinase |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15112771.3A HK1211928A1 (en) | 2012-09-28 | 2015-12-28 | Azaquinazoline inhibitors of atypical protein kinase |
Country Status (19)
Country | Link |
---|---|
US (2) | US9914730B2 (xx) |
EP (1) | EP2900666B1 (xx) |
JP (1) | JP6535430B2 (xx) |
KR (1) | KR102215272B1 (xx) |
CN (1) | CN105102456B (xx) |
AU (1) | AU2013323360B2 (xx) |
BR (1) | BR112015007061B1 (xx) |
CA (1) | CA2886495C (xx) |
CL (1) | CL2015000781A1 (xx) |
EA (1) | EA030253B1 (xx) |
HK (2) | HK1211928A1 (xx) |
IL (1) | IL237918B (xx) |
MX (1) | MX2015004016A (xx) |
NZ (1) | NZ706857A (xx) |
PH (1) | PH12015500689A1 (xx) |
SG (1) | SG11201502301YA (xx) |
TW (1) | TWI663165B (xx) |
WO (1) | WO2014052699A1 (xx) |
ZA (1) | ZA201502783B (xx) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102215272B1 (ko) * | 2012-09-28 | 2021-02-15 | 이그니타, 인코포레이티드 | 비정형 단백질 키나제 c의 아자퀴나졸린 억제제 |
WO2014100501A1 (en) | 2012-12-20 | 2014-06-26 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
AU2014230814B2 (en) | 2013-03-14 | 2017-12-21 | Boehringer Ingelheim International Gmbh | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C |
HUE043465T2 (hu) | 2013-08-23 | 2019-08-28 | Neupharma Inc | Kémiai anyagok, készítmények és módszerek |
WO2015143376A1 (en) * | 2014-03-21 | 2015-09-24 | Nivalis Therapeutics, Inc. | Novel compounds for the treatment of cystic fibrosis |
TWI675836B (zh) | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | 非典型蛋白質激酶c之氮雜喹唑啉抑制劑 |
WO2015200534A2 (en) | 2014-06-25 | 2015-12-30 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
US9580416B2 (en) | 2014-07-02 | 2017-02-28 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
EP3189052B1 (en) | 2014-09-05 | 2021-11-03 | The Johns Hopkins University | Camkii inhibitors and uses thereof |
LT3191487T (lt) | 2014-09-12 | 2019-10-10 | Boehringer Ingelheim International Gmbh | Katepsino c spirocikliniai inhibitoriai |
CA2962917C (en) * | 2014-10-29 | 2019-04-30 | Dong-A St Co., Ltd. | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) |
CN105288512A (zh) * | 2015-12-08 | 2016-02-03 | 李野林 | 一种治疗肥胖症的中药组合物 |
JP7051829B2 (ja) | 2016-06-13 | 2022-04-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Dnmt1の阻害剤としての置換ピリジン |
AU2017312561B2 (en) | 2016-08-15 | 2022-06-30 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
JP6954994B2 (ja) * | 2016-08-16 | 2021-10-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 可逆性btk阻害剤としてのオキソ−イミダゾピリジン及びその使用 |
BR112019005046A2 (pt) | 2016-09-19 | 2019-06-18 | Novartis Ag | combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk |
JOP20190257A1 (ar) * | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
US10329282B2 (en) | 2017-06-30 | 2019-06-25 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
WO2019001572A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
JP7039802B2 (ja) | 2017-06-30 | 2022-03-23 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Rho-関連プロテインキナーゼ阻害剤、rho-関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用 |
KR102603203B1 (ko) * | 2018-07-25 | 2023-11-16 | 파에스 파마, 에스.에이. | 히스타민 h4-수용체 저해제로서 피리도피리미딘류 |
CN112638899B (zh) * | 2018-08-01 | 2023-09-05 | 上海轶诺药业有限公司 | 一类具有免疫调节功能的芳香化合物的制备和应用 |
CN111100063B (zh) * | 2018-10-25 | 2022-05-17 | 南京药石科技股份有限公司 | 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法 |
EP3947380A4 (en) * | 2019-03-28 | 2023-01-11 | Cancer Research Technology Ltd | INHIBITORS OF ATYPICAL PROTEIN KINASE C AND THEIR USE IN THE TREATMENT OF HEDGEHOG PATHWAY-DEPENDENT CANCER |
CN114349711B (zh) * | 2022-02-28 | 2023-08-15 | 四川依维欣医药科技有限公司 | 一种(R)-1-Boc-3-羟甲基哌嗪的合成方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4936700A (xx) | 1972-08-16 | 1974-04-05 | ||
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
JP2002080423A (ja) * | 2000-09-06 | 2002-03-19 | Daikin Ind Ltd | トリフルオロ酢酸エチルの合成方法 |
AU2001291013A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP4895806B2 (ja) * | 2003-04-09 | 2012-03-14 | エクセリクシス, インク. | Tie−2モジュレータと使用方法 |
US20050038047A1 (en) * | 2003-08-14 | 2005-02-17 | Edwards Paul John | Azaquinazoline derivatives |
US7582631B2 (en) * | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
KR20070113252A (ko) * | 2005-02-25 | 2007-11-28 | 쿠도스 파마슈티칼스 리미티드 | 2,4-디아미노-피리도피리미딘 유도체 및 이의 mTOR억제제로서의 용도 |
LT2057156T (lt) * | 2006-08-23 | 2017-05-25 | Kudos Pharmaceuticals Limited | 2-metilmorfolino pirido-, pirazo- ir pirimidopirimidino dariniai kaip mtor slopikliai |
BRPI0716880A2 (pt) * | 2006-09-08 | 2013-10-15 | Pfizer Prod Inc | Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas |
EP2473054B1 (en) * | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
KR102215272B1 (ko) * | 2012-09-28 | 2021-02-15 | 이그니타, 인코포레이티드 | 비정형 단백질 키나제 c의 아자퀴나졸린 억제제 |
EP2968342B1 (en) * | 2013-03-13 | 2018-10-03 | The Regents of the University of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
WO2016040330A1 (en) * | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
MX2018007703A (es) * | 2015-12-22 | 2018-11-09 | Vitae Pharmaceuticals Inc | Inhibidores de la interaccion de menina-linaje leucemico mixto. |
-
2013
- 2013-09-27 KR KR1020157010868A patent/KR102215272B1/ko active IP Right Grant
- 2013-09-27 EA EA201590661A patent/EA030253B1/ru not_active IP Right Cessation
- 2013-09-27 CN CN201380062263.9A patent/CN105102456B/zh active Active
- 2013-09-27 AU AU2013323360A patent/AU2013323360B2/en active Active
- 2013-09-27 TW TW102134928A patent/TWI663165B/zh active
- 2013-09-27 SG SG11201502301YA patent/SG11201502301YA/en unknown
- 2013-09-27 EP EP13774578.2A patent/EP2900666B1/en active Active
- 2013-09-27 MX MX2015004016A patent/MX2015004016A/es active IP Right Grant
- 2013-09-27 CA CA2886495A patent/CA2886495C/en active Active
- 2013-09-27 US US14/038,915 patent/US9914730B2/en active Active
- 2013-09-27 WO PCT/US2013/062085 patent/WO2014052699A1/en active Application Filing
- 2013-09-27 JP JP2015534689A patent/JP6535430B2/ja active Active
- 2013-09-27 BR BR112015007061-2A patent/BR112015007061B1/pt active IP Right Grant
- 2013-09-27 NZ NZ706857A patent/NZ706857A/en unknown
-
2015
- 2015-03-24 IL IL237918A patent/IL237918B/en active IP Right Grant
- 2015-03-26 PH PH12015500689A patent/PH12015500689A1/en unknown
- 2015-03-27 CL CL2015000781A patent/CL2015000781A1/es unknown
- 2015-04-23 ZA ZA2015/02783A patent/ZA201502783B/en unknown
- 2015-12-18 US US14/975,605 patent/US9896446B2/en active Active
- 2015-12-28 HK HK15112771.3A patent/HK1211928A1/xx unknown
-
2016
- 2016-01-08 HK HK16100191.9A patent/HK1212336A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212336A1 (en) | Azaquinazoline inhibitors of atypical protein kinase | |
HK1215577A1 (zh) | 蛋白激酶抑制劑 | |
HK1202529A1 (zh) | 非典型性蛋白激酶 的噻吩並嘧啶類抑制劑 | |
HK1200451A1 (zh) | 蛋白激酶抑制劑 | |
HK1198360A1 (en) | Heterocyclic protein kinase inhibitors | |
EP2694517A4 (en) | PROTEIN KINASE INHIBITORS | |
ZA201306855B (en) | Protein kinase inhibitors | |
EP2833889A4 (en) | PROTEIN KINASE C HEMMER AND USES THEREOF | |
HK1209726A1 (en) | Protein kinase inhibitors | |
HK1205506A1 (en) | Protein kinase inhibitors | |
HK1208460A1 (en) | Protein kinase inhibitors | |
HK1213252A1 (zh) | 雙環二氫吡啶酮激酶抑制劑 | |
EP2838531A4 (en) | INDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | |
HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
HK1210036A1 (en) | Aminoisoquinoline derivatives as protein kinase inhibitors | |
HK1201066A1 (en) | Pyranopyridone inhibitors of tankyrase | |
EP2988738A4 (en) | THERAPEUTIC APPLICATIONS OF KINASEHEMMERN | |
PL2888228T3 (pl) | Inhibitory oddziaływania CD40-TRAF6 | |
HK1213181A1 (zh) | 雙環氧雜內酰胺激酶抑制劑 | |
GB201323021D0 (en) | Use of kinase inhibitors | |
GB201321227D0 (en) | Use of kinase inhibitors |